Messenger ribonucleic acid (mRNA) is a single-stranded molecule that is complementary to a gene’s DNA. It is important in part of the protein engineering market because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein. In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. The IVT mRNAs are structurally similar to natural mRNAs, these synthetic mRNAs can be used to express proteins through genetic engineering. It is worth noting that several companies have begun to develop mRNA therapeutics for the treatment / prevention of various infectious diseases. Furthermore, these candidate therapies can be used to develop precise and individualized therapies that allow patients to produce therapeutic proteins in their own bodies. Given the numerous benefits of mRNA vaccines / therapeutics and the increased demand for such therapeutic modality as a result of the recent COVID-19 pandemic, we believe that the mRNA therapeutics and mRNA vaccines market will experience significant growth in the near future.
mRNA Therapeutics and Vaccines Delivery Routes
Efficient delivery of both therapeutic and vaccine candidates plays a key role in ensuring the effective expression and presentation of antigens. mRNA therapeutics can be delivered via the below-mentioned approaches.
Applications of mRNA Vaccines and Therapeutics
The below figure highlights the various applications of the mRNA-based therapeutics.
The following points illustrate the key applications of mRNA therapeutics and vaccines:
Allergy Tolerization Therapies: Plasmid DNA and mRNA vaccines that encode for allergens have been demonstrated to be capable of inducing T helper 1 cells and T regulatory responses, which, in turn, can modulate allergic reactions caused due to T helper 2 cells.
Cancer Immunotherapies: RNA molecules, such as siRNA, microRNA, and mRNA, have shown tremendous potential for immunomodulation and use as a cancer immunotherapy. Further, these can be used to activate both innate and adaptive immune system responses by silencing or upregulating immune-relevant genes.
Genome Engineering: mRNA therapeutics have been demonstrated to be capable of editing genomic DNA sequences in an efficient and precise manner, thereby, making them potential candidates for the treatment of genetic disorders.
Protein Replacement Therapies: Gene therapy can be defined as transplantation of normal genes, in order to replace missing or defective genes, with an aim to correct genetic disorders or promote inactive beneficial mechanisms or pathways. mRNA drugs are considered to offer an effective alternative to gene therapies, specifically for protein replacement, as they avoid the risk of genome integration and offer strong transient expression.
Prevention of infectious diseases: Development of a prophylactic or therapeutic vaccine is one of the most effective ways to contain and fight an epidemic / pandemic. It is worth mentioning that several companies engaged in this domain have already evaluated mRNA-based therapies for the treatment of infectious diseases; these products were demonstrated to have promising safety profiles. The two major types of RNA vaccines that are being developed for infectious diseases are self-amplifying or replicon RNA vaccines, and non-replicating mRNA vaccines. The two mRNA vaccine candidates, namely BNT162b2 (BioNTech) and mRNA-1273 (Moderna) were the first mRNA vaccine to receive emergency use approval in several countries for the prevention of COVID-19.
Treatment of oncological disorders: Cancer vaccines are designed to target tumor-specific antigens, which are usually expressed in cancer cells; referred to as neoantigens. It is worth mentioning that neoantigens or their epitopes can be used as mRNA vaccine targets in humans. Multiple preclinical and clinical studies have reiterated the ability of mRNA vaccines to treat oncological disorders.
What are the key trends that are shaping up the mRNA vaccines and therapeutics market?
As per a recent market report by Roots Analysis, more than 195+ mRNA-based therapeutics and vaccines are being investigated by various mRNA companies across the world. In addition, numerous partnerships were established in this domain, during the period 2013-2022.
Keeping every trend in mind, Roots Analysis has provided complete information on market trends in mRNA-based vaccines / therapeutics domain, which has some of the very recent and precise activities listed for the clients to help them make better decisions in its report titled, mRNA Therapeutic and Vaccines Market, 2022-2035. To find answers to key decision-making question and to know further about the market forecast analysis, highlighting the likely growth of the mRNA Therapeutics and Vaccine Market, for the time period 2022-2035.
For further information on this market, access the SAMPLE PAGES on our latest mRNA therapeutics and vaccine market report.
With an experience of over 4 years with Roots Analysis, Jasmeet is adept at generating useful insights from unstructured / structured datasets. As a senior analyst at Roots Analysis, she has assisted several clients across multiple industry verticals within the healthcare domain. These verticals include, contract services, devices / technologies, and drugs / disease indications. Since the findings of the research are aimed at supporting the clients to make thoughtful decisions for their business, she has hands-on experience on competitive landscape assessment, benchmarking, market sizing and forecasting, as well as several quantitative / qualitative / strategic frameworks